KRAS and familial pancreatic carcinoma: In addition, YAP acts downstream of mutant KRAS, and activation of YAP was found to drive KRAS-independent tumor relapse in preclinical models of pancreatic cancer (Kapoor et al., 2014; Shao et al., 2014; Zhang et al., 2014).